Premium
An Outbreak of Non‐A, Non‐B Hepatitis Associated with the Infusion of a Commercial Factor IX Complex during Cardiovascular Surgery 1
Author(s) -
Gerber A. R.,
Englender S. J.,
Selvey D.,
Carlson J. F.,
Matthews D. L.,
Webster H. M.,
Caldwell G. G.
Publication year - 1990
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1990.tb04998.x
Subject(s) - medicine , clotting factor , outbreak , risk factor , hepatitis b , population , factor ix , surgery , incubation period , gastroenterology , virology , incubation , environmental health , biochemistry , chemistry
. An outbreak of non‐A, non‐B hepatitis was recognized among cardiovascular surgical patients from one hospital in June 1985. Illness was found to be significantly associated with a commercial brand of factor IX complex given to patients because of intraoperative bleeding. A change in the commercial brand of factor IX stocked by the hospital pharmacy had occurred in October 1984 and coincided with the onset of the outbreak. A retrospective study of cardiovascular surgery patients identified 23 cases and 7 probable cases of non‐A, non‐B hepatitis among patients who had received infusions of brands A and B factor IX complex. Three cases were in brand A recipients and 27 were in brand B recipients. Respective brand‐specific attack rates were 5 and 42% (relative risk = 7.7; p<2 × l0 ‐5 ; χ 2 test). Nineteen of 30 case patients (63%) were jaundiced, including 2 brand A recipients and 17 brand B recipients. Median peak serum aminotransferase was 690.5 IU (range 27–2,824). The incubation period for cases in brand B recipients was a median of 7 weeks (range 2–17 weeks). Prevention of non‐A, non‐B hepatitis in this population requires adhering to strict indications for the use of clotting factor preparations and avoiding these products when at all possible. Heat treatment of clotting factor products may reduce the risk of viral disease transmission, but certain methods may not inactivate the causative agents of non‐A, non‐B hepatitis.